Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma

Cancer

Volumn 94, Issue 4 SUPPL., 2002, Pages 1202-1209

  Supiot, Stephane ^a   Faivre Chauvet, Alain ^a   Couturier, Olivier ^a   Heymann, Marie Françoise ^b   Robillard, Nelly ^a   Kraeber Bodéré, Françoise ^a   Morandeau, Laurence ^a   Mahé, Marc Andrè ^c   Chérel, Michel ^a  

^a INSTITUT DE BIOLOGIE   (France)

^b CHU de Nantes   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Bismuth 213; Cell cycle; Iodine 131; Muc1; Multiple myeloma; Radioimmunotherapy; Syndecan 1

Indexed keywords

BISMUTH 213; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B B4 BI 213; MONOCLONAL ANTIBODY B B4 I 131; MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY MA5 BI 213; MONOCLONAL ANTIBODY MA5 I 131; MUCIN 1; PROPIDIUM IODIDE; SYNDECAN 1; UNCLASSIFIED DRUG; CHELATING AGENT; DNA; PENTAACETIC TRIAMINE DIETHYLENE 4 AMINOBENZOIC ACID; RADIOPHARMACEUTICAL AGENT;

CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL DEATH; CLONOGENIC ASSAY; CONFERENCE PAPER; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IRRADIATION; ISOTOPE LABELING; MULTIPLE MYELOMA; PRIORITY JOURNAL; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG TARGETING; DUODENUM; G2 PHASE CELL CYCLE CHECKPOINT; HEMATOPOIETIC CELL; HEMATOPOIETIC TISSUE; HUMAN TISSUE; IN VITRO STUDY; KIDNEY PARENCHYMA; LIVER PARENCHYMA; LUNG PARENCHYMA; MOLECULAR RECOGNITION; MTT ASSAY; MULTIPLE MYELOMA CELL LINE; PROTEIN EXPRESSION; RADIOACTIVITY; TIME;

EID: 0037083548     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10286     Document Type: Conference Paper

References (32)

1. Multiple myeloma
2. Clinical radioimmunotherapy
3. Radioimmunotherapy with alpha-emitting nuclides
4. 213Bi-alpha radioimmunotherapy for multiple myeloma
5. B-B2 and B-B4, two new Moabs against secreting plasma cells
6. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1
7. Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins
8. Identification and location on syndecan-1 core protein of the epitopes of B-B2 and B-B4 monoclonal antibodies
9. Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma
10. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma
11. Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone
12. The epithelial mucin, MUC1, of milk, mammary gland and other tissues
13. 111In-labeled monoclonal antibody (MA5) against a mucin-like antigen
14. Synthesis of 1-(p-Isothiocyanatobenzyl) Derivatives of DTPA and EDTA: Antibody labeling and tumor imaging studies
15. Cytotoxicity of 213Bi- and 225Ac-immunoconjugates
16. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6-alpha-diphenyl glycoluril (Iodogen)
17. Relationship between internalization and cytotoxicity of ricin A-chain immunotoxins
18. Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy
19. The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y
20. Dosimetric aspects of radiolabeled antibodies for tumor therapy
21. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts
22. Delayed iniation of DNA synthesis in irradiated human diploid cells
23. p53 and RAS gene mutations in multiple myeloma
24. Mutations of the p53 gene in human myeloma cell lines
25. 2/M delay and cellular radiosensitivity
26. Substructure in the radiation survival response at low dose: Asynchronous and partially synchronized V79-WNRE cells
27. 2/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation
28. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody
29. The treatment of multiple myeloma
30. Antitumor activity of thalidomide in refractory multiple myeloma
31. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma